Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells

Clinical trials of imetelstat therapy have indicated that this telomerase inhibitor might have disease-modifying effects in a subset of patients with myelofibrosis (MF). The mechanism by which imetelstat induces such clinical responses has not been clearly elucidated. Using in vitro hematopoietic pr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Wang, Xiaoli, Hu, Cing Siang, Petersen, Bruce, Qiu, Jiajing, Ye, Fei, Houldsworth, Jane, Eng, Kevin, Huang, Fei, Hoffman, Ronald
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2018
Ämnen:
Myeloid Neoplasia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156882/
https://ncbi.nlm.nih.gov/pubmed/30242099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022012
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk